PegBio Co., Ltd. (02565) announced that CR059, a next-generation GLP-1 receptor agonist developed with circular RNA protein replacement technology and an AI-assisted molecular design platform, has completed a single-dose administration in human subjects and obtained one-month clinical observations. This development is part of the phased strategy for the PB-2309 triple receptor (GLP-1/GIP/GCG) agonist program.
CR059 employs a lipid nanoparticle delivery system to provide long-acting metabolic intervention through sustained in vivo expression of GLP-1 receptor agonists. Preclinical studies in db/db mice showed superior metabolic intervention compared to semaglutide with a clear dose-response trend. In a spontaneous type 2 diabetes model of rhesus monkeys, monthly subcutaneous injections significantly improved fasting plasma glucose and reduced glycated hemoglobin levels, with continued improvement observed until Day 88. A single subcutaneous injection in healthy rhesus monkeys also supported low-frequency administration by achieving a weight loss of approximately 11.8% after five weeks.
The ongoing first-in-human study in type 2 diabetes mellitus aims to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic profiles of CR059. Four weeks after a single administration, glycated hemoglobin and fasting blood glucose continued to improve. Continuous glucose monitoring data demonstrated an increased time in target range (4-10 mmol/L) and a notable decrease in mean blood glucose. These findings suggest a sustained metabolic improvement trend.
PegBio’s circular RNA platform optimizes the codon structure design and uses high-expression IRES elements for stable protein translation without a 5′cap or poly(A) tail, potentially supporting a long-term, low-frequency treatment model for chronic metabolic disorders. Nonetheless, there is no guarantee of ultimate successful development or marketing of CR059, and caution is advised when dealing in the company’s securities.
Comments